Company profile: Tempest Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics that modulate anti-tumor pathways, including TPST-1120, an oral PPARΞ± antagonist designed to inhibit fatty acid oxidation and inflammation with potential in hepatocellular, renal cell, and cholangiocarcinoma, and TPST-1495, an oral dual EP2/EP4 antagonist in Phase 1/1b combination studies to reduce tumor growth and immune suppression.
Products and services
- Small Molecule Therapeutics Portfolio: Architects small-molecule products that modulate anti-tumor pathways, addressing fatty acid oxidation, prostaglandin EP2/EP4 signaling, and inflammation to impact tumor growth and immune suppression
- TPST-1495: Produces an oral dual-receptor antagonist of EP2 and EP4 in the prostaglandin pathway, diminishing tumor growth and immune suppression, with ongoing Phase 1/1b combination studies
- TPST-1120: Engineers an oral PPARΞ±-selective antagonist that inhibits fatty acid oxidation and inflammation, showing potential in hepatocellular, renal cell, and cholangiocarcinoma indications
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Tempest Therapeutics
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Carrick Therapeutics company profile β
ClearNote Health
HQ: United States
Website
- Description: Provider of cancer detection solutions, including the Avantect Pancreatic Cancer Testβa blood test that detects pancreatic cancer in its earliest stages by measuring the biomarker 5hmC; the Virtuoso Epigenomics Platformβa whole genome sequencing and 5hmC enrichment solution for revealing active disease biology for drug discovery and development; and targeted multi-cancer panels that track epigenomic signals via a single blood draw.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full ClearNote Health company profile β
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Tilos Therapeutics company profile β
Abingdon Health
HQ: United Kingdom
Website
- Description: Provider of rapid and near-patient medical diagnostic testing solutions as an innovative, technology-led company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Abingdon Health company profile β
VelosBio
HQ: United States
Website
- Description: Provider of clinical-stage, next-generation oncology therapeutics, developing first-in-class ROR1-directed treatments, including novel antibody-drug conjugates for hematologic and solid tumors; offerings include injection-based therapies such as WINREVAIR (sotatercept-csrk) and KEYTRUDA (pembrolizumab).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full VelosBio company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Tempest Therapeutics
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tempest Therapeutics
2.2 - Growth funds investing in similar companies to Tempest Therapeutics
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Tempest Therapeutics
4.2 - Public trading comparable groups for Tempest Therapeutics
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β